Gyroscope Therapeutics was founded in 2016 based on the scientific work of Professor Sir Peter Lachmann at the University of Cambridge, with further contribution by David Kavanagh at Newcastle University and Andrew Lotery at the University of Southampton.
Gyroscope is developing cutting edge, genetically defined therapies for the treatment of eye diseases linked to an unbalanced complement system, which is a part of the immune system. It is exploring the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of age-related macular degeneration (AMD) and gene therapy as a mode of treatment delivery.
Gyroscope’s lead product, GT005 (the FOCUS study), is a novel retinal gene therapy aimed at delivering a targeted, one-time treatment to genetically defined patients with advanced dry AMD. Beyond GT005, Gyroscope is building a pipeline of gene therapy products for the treatment of eye diseases with high unmet medical need.
In April 2019, the company announced the merger with Orbit Biomedical, a medical device company focused on the precise and targeted delivery of gene and cell therapies to the retina. In addition, the company announced the appointment of Kjurem Farooq as CEO to lead the team into its next phase of development.
CIC invested in Gyroscope, taking up Cambridge Enterprise’s pre-emption rights as part of Gyroscope’s Series A funding.
CIC point of contact: Robert Tansley